is pleased to introduce the Living Medical Textbook™ — an interactive resource that builds a knowledge base through a series of educational modules.
In every chapter of a Living Medical Textbook™
you will find supportive multimedia hyperlinks to illustrations, videos, journal articles, glossary terms, online textbooks, and other resources which enhance the relevant
issues in the text.
As a "living" resource,
the educational content will be periodically updated. Each edition of Living Medical Textbook™
offers free AMA PRA Category
1 Credits™


Type 2 Diabetes Milletus in Practice![]() Newly Updated Chapter |
|
Chapter 1 - Goals of Treatment for Comprehensive care of patients with type 2 diabetes mellitus (T2DM) includes aggressive management of this disease. It is critically important for patients with T2DM to meet target goals for glycemic control and long-term goals to prevent complications, such as hypertension, dyslipidemia, kidney failure, etc. In this first chapter of the Living Medical Textbook™: Diabetes Edition: Type 2 Diabetes Mellitus in Practice, Alan J. Garber, MD, PhD, reviews both short- and long-term goals of care for patients with T2DM based on current guidelines and evidence-based medicine. Preventing chronic complications of T2DM is vital in reducing the morbidity and mortality associated with this serious disease. Chapter 2 - DPP-4 and Its Inhibitors in What is the function of DPP-4 and how does it affect glucose levels? Why is it a relevant therapeutic target in T2DM? How do DPP4 inhibitors help reduce hyperglycemia in T2DM? Janet B. McGill, MD, answers these questions by explaining the science behind DPP-4 and its inhibitors. Chapter 3 - DPP-4 Inhibitors: Two FDA-approved formulations of dipeptidyl peptidase 4 (DPP-4) inhibitors are currently available. In the third chapter of the Living Medical Textbook™: Diabetes Edition: Type 2 Diabetes Mellitus in Practice, Janet B. McGill, MD, reviews current data on their efficacy and safety. In addition, she provides practical information on how to best put them to use, identifying their most appropriate role in combination regimens, and explaining how to dose them and manage side effects. Chapter 4 - SGLT2 and Its Inhibitors in What is the function of sodium glucose cotransporter 2 (SGLT2) and how does it affect glucose levels? Why is it a relevant therapeutic target in type 2 diabetes mellitus (T2DM)? Do SGLT2 inhibitors in development have potential to reduce hyperglycemia in T2DM? In the fourth chapter of the Living Medical Textbook™: Diabetes Edition: Type 2 Diabetes Mellitus in Practice, Vivian Fonseca, MD, provides a detailed explanation of the science behind this emerging class of therapies for T2DM. Chapter 5 - SGLT2 Inhibitors: Sodium glucose cotransporter 2 (SGLT2) inhibitors are emerging as an exciting new class of therapies for type 2 diabetes mellitus (T2DM), with four agents currently in development. In this fifth chapter of the Living Medical Textbook™: Diabetes Edition: Type 2 Diabetes Mellitus in Practice, Vivian Fonseca, MD, reviews current data on their efficacy and safety. In addition, he provides practical information on dosing and side effect management and considers where they might fit into the current armamentarium for the treatment of T2DM. |

Insights into Managing Leukemia & MDS Edition![]() |
|
Chapter 1 - Overview of Leukemia Chapter 2 - Lymphoid Leukemia Chapter 3 - Myeloid Leukemia Chapter 4 - Myelodysplastic Syndromes |

Parkinson's Disease Edition: Early Diagnosis and Management Edition ![]() |
|
Chapter 1 - Parkinson's Disease: The Importance of Chapter 2 - Clinical Trial Design in Parkinson's Disease Chapter 3 - MAO-B Inhibitors in Parkinson's Disease: |
Multiple Sclerosis 2010 Edition ![]() |
|
Chapter 1 - Multiple Sclerosis Basics Chapter 2 - MRI and New Imaging Technologies in Chapter 3 - Currently Available Treatments for Chapter 4 - Small-Molecule Treatments in Chapter 5 - Monoclonal Antibodies in Development Chapter 6 - Managing Symptoms in Multiple Sclerosis |

Update to the Tumor Immunology and Immunotherapy: Metastatic Melanoma Edition ![]() |
Chapter 1 - Immunology in Review Chapter 2 - Tumor-Fighting T-Cells Chapter 3 - Costimulation and the T-Cell Response Chapter 4 - Targeting Immune Stimulation: Chapter 5 - Autoimmune Effects of Chapter 6 - New and Emerging Agents in the |
Women's Cancers Edition![]() |
Chapter 1 - Chemotherapy in Recurrent or Chapter 2 - Current Management of Chapter 3 - Frontline Management of Chapter 4 - Recurrent Ovarian Cancer: Chapter 5 - Early Breast Cancer— Chapter 6 - Targeted Agents and Chemotherapy |

Fracture Prevention and Therapeutic Management Edition ![]() |
Chapter 1 - Overview of Osteoporosis Chapter 2 - Identifying Patients at Risk for Chapter 3 - Assessment of Fracture Risk Using FRAX® Chapter 4 - Treatment of Osteoporosis Chapter 5 - Management of the Postfracture Patient Chapter 6 - Monitoring |
